Stocks of Roivant Sciences Ltd (NASDAQ:ROIV) traded higher last session on Wall Street, up 0.27% to $10.97.
ROIV stock price is now -1.40% away from the 50-day moving average and -2.11% away from the 200-day moving average. The market capitalization of the company currently stands at $7.46B.
With the price target of $17, Wolfe Research recently initiated with Outperform rating for Roivant Sciences Ltd (NASDAQ: ROIV). On January 05, 2024, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $20, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, Venker Eric, President & COO sold 100,000 shares of the company’s stock on Jun 20 ’25. The stock was sold for $1,145,000 at an average price of $11.45. Upon completion of the transaction, the President & COO now directly owns 1,462,223 shares in the company, valued at $16.04 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 20 ’25, 10% Owner Ramaswamy Vivek sold 577,007 shares of the business’s stock. A total of $6,612,500 was realized by selling the stock at an average price of $11.46. This leaves the insider owning 37,284,108 shares of the company worth $409.01 million. A total of 39.03% of the company’s stock is owned by insiders.
During the past 12 months, Roivant Sciences Ltd has had a low of $8.73 and a high of $13.06. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 33.47, and a quick ratio of 33.47.
The net profit margin was -225.71% and return on equity was -8.56% for ROIV. The company reported revenue of -$39.57 million for the quarter, compared to -$8.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 387.28 percent.
